The physical location of a primary tumor may be an indicator of survivor in patients with metastatic colorectal cancer (mCRC), according to results from a large retrospective study presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL (June 3-7, 2016).
A recent study examined the association between colorectal cancer messenger RNA (mRNA) expression of HER3 with response to anti-EGFR agents, published in JAMA Oncology (online October 26, 2017; doi:10.1001/jamaoncol.2017.3168).
A pooled analysis investigated the prognostic role of DNA mismatch repair (MMR) status in patients with stage III colon cancer treated with a standard adjuvant chemotherapy regimen, published in JAMA Oncology (online October 5, 2017; doi:10.1001/jamaoncol.2017.2899).
Over-the-counter heartburn and gastrointestinal drugs, such as proton pump inhibitors (PPIs), may decrease the effectiveness of chemotherapy in patients with gastroesophageal cancer (GEC), according to a new study published in JAMA Oncology.
The recently published US Preventative Services Task Force (USPSTF) updated recommendation statement on colorectal cancer screening referenced multiple available options for colorectal screening, including Epigenomics’ Epi proColon.
Patients with stage II or stage III rectal cancer may have better outcomes when treated with surgery and chemoradiotherapy than those who receive chemoradiotherapy alone, according to an article published in JAMA Oncology.